New discoveries in lung cancer research, such as the research funded by LCFA, are resulting in new treatments for lung cancer patients

How LCFA uses your donation wisely to fight lung cancer:

You Make A Donation to LCFA
Your dollars are added to contributions from other donors

We maximize your donation by adding it to dollars from LCFA’s strategic funding partners.

This leveraged donation allows LCFA to award a generous grant to a top young lung cancer investigator for 2 years of focused and intense research.

The lung cancer investigator
can now start the critical two-year process of research and discovery

Now, armed with this new evidence, the lung cancer investigator presents their findings to organizations like the National Institutes of Health (NIH) for consideration for vital next-stage grants.

Each painstaking step brings us closer to understanding how lung cancer works, how to detect it earlier, how to fight it better, and – someday – how to cure it.

Latest In Research


Pre-surgical Immunotherapy Trial to Open at UCLA Main Campus

Pre-surgical Immunotherapy Trial UCLA Main Campus: Stage IB, II, IIIA non-small cell lung cancer Exciting announcement from Thoracic Oncology Translational Research at UCLA: Upcoming opening of a pre-surgical immunotherapy trial for…


AACR Annual Meeting 2017: Panel Discusses the Affordable Care Act

Can we make the ACA better? The legislation was the focus of a panel held at the American Association for Cancer Research Annual Meeting 2017. Read more:…


AACR Annual Meeting 2017: Immunotherapy Provides Long-lasting Responses to Certain Cancer Types

  Are responses to immunotherapy for lung cancer durable? According to data presented at AACR's 2017 Annual Meeting, from a number of clinical trials, the answer appears to be “Yes.” For many patients whose cancers responded …


Phase III Study Shows Genentech’s Alecensa® Was Superior to Crizotinib in a Specific Type of Lung Cancer

A recent study shows that Alecensa® as an initial (first-line) treatment significantly reduced the risk of disease worsening or death compared to crizotinib in people with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell …


Drug Offers Some Hope for a Deadly Lung Cancer

The cancer drug Opdivo (nivolumab) may offer hope of a longer life for some patients with advanced lung cancer, a new small study finds. Currently, only about 5 percent of patients with advanced non-small-cell lung cancer survive five years …


‘Bad luck’ mutations increase cancer risk more than behavior, study says

For the first time, researchers have estimated what percentage of cancer mutations are due to environmental and lifestyle factors, hereditary factors and random chance. Overall, 66% of the genetic mutations that develop into cancer are caused…


Frontline Immunotherapy Trial for EGFR Mutation Positive Patients to Expand Enrollment

Announcing the investigator initiated trial Pembro IST is anticipated to expand enrollment to UCLA satellite sites. Pembrolizumab is an antibody that inhibits the PD-1/PD-L1 immune checkpoint and allows the immune system to des…


Advice From Patients On A Study’s Design Makes For Better Science

Clinical Trials News:  NCI-MATCH trial upends the normal way of classifying cancers for treatment: Instead of categorizing malignancies by the organ where they first appear, this method of sorting focuses on particular mutations in the ge…


Update: CRISPR

Scientists say they’ll someday be able to use CRISPR to fight cancer and maybe even bring animals back from the dead. Read the story:…


Trial for Patients Doing Well on Nivolumab Expands to UCLA

The Checkmate 384 study will is now available at UCLA sites in addition to the sites already open in the TRIO-US network. This study is a dose frequency optimization trial of nivolumab in patients with Stage IIIB or Stage IV squa…

Read More